Engflag

Lactospore

Quick links to important sections

Lactospore

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lactospore

Property Description
Active Ingredient Bacillus coagulans MTCC 5856
Form Spore (Powder, Capsule, Tablet)
Pharmacological Class Probiotic / Lactic Acid-Producing Microbial Agent
General Use Support of intestinal microecology and digestive health
Origin Natural (Microbial strain)

Identity and Classification

Lactospore^registered is a specific, single-strain ingredient classified as a spore-forming probiotic and a nutraceutical ingredient. Its active component is the bacterial strain Bacillus coagulans MTCC 5856. It belongs to the high-level pharmacological class of Lactic Acid-Producing Microbial Agents. This preparation is recognized for supporting the healthy balance of the gut's microbial community.

This strain, which is of natural origin, was historically referred to as Lactobacillus sporogenes, a name that acknowledged its ability to produce lactic acid. However, the current taxonomic classification recognizes its membership in the Bacillus genus due to its defining feature: the production of a resilient spore. The preparation is intended for oral ingestion.

Unique Features and Physical Form

The primary differentiating factor of Lactospore^registered is its physical structure as a preparation of resilient bacterial spores. This protective, dormant spore confers exceptional resistance against environmental stressors, ensuring stability even under high heat and through the acidic environment of the stomach. This unique type of formation results in a preparation that is both thermostable and highly shelf-stable, reducing the need for cold storage.

Clinical research has confirmed that B. coagulans exhibits stability throughout the upper gastrointestinal tract, ensuring effective delivery to the intestine. Once the spore successfully navigates the stomach, it germinates (activates) and begins to multiply in the gut.

General Purpose

The purpose of Lactospore^registered is to act as a microbial supplement to support and maintain a healthy intestinal microecology. The active bacteria produce L(+) Lactic Acid, which helps to optimize the pH level in the gut. By assisting in the maintenance of a favorable microbial balance, Lactospore^registered is typically used to support overall digestive health and promote the natural function of the bowel.

Regulatory References

  1. NIH Review on Bacillus coagulans MTCC 5856

What side effects are possible with Lactospore?

Possible Side Effects and Safety Information

Bacillus coagulans MTCC 5856 (Lactospore) is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration (FDA) for its intended uses. This regulatory status defines the fundamental safety characteristics of the ingredient.

Adverse events reported during controlled clinical studies are generally observed at rates similar to those in the placebo groups, meaning they are not typically classified as treatment-emergent side effects.

Adverse Reaction Scope

Classification Official Regulatory Statement
Frequency Standard pharmaceutical frequency terms are not applied; AEs are similar to placebo rates.
System-Organ Classes Primarily Gastrointestinal Disorders (e.g., bloating, gas, abdominal pain).
Serious Reactions No treatment-related serious adverse events have been reported in human clinical trials. Theoretical risks of systemic infection are noted in reviews for specific high-risk groups.

Special Safety Considerations

Safety notes from regulatory reviews indicate caution is appropriate for certain populations. This includes immunocompromised individuals who may face a higher theoretical risk of systemic infection, and premature infants, a group noted for increased susceptibility to severe adverse effects from probiotics generally.

Furthermore, official assessments confirm that this specific strain does not possess genes for antibiotic resistance that would compromise clinically important antibiotics, nor does it contain genes homologous to those encoding for known bacterial toxins. These determinations support the low-risk profile as established by its GRAS status.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation for Bacillus coagulans MTCC 5856 (Lactospore) does not describe a specific toxic syndrome or specific clinical manifestations resulting from overdose. This is consistent with its classification as a microbial agent with generally low systemic toxicity, which does not necessitate the detailed toxicological profiles required for systemic pharmaceutical drugs.

Official Regulatory Statements on Overdose

Classification Focus Documented Information
Specific Toxicity Absence of a specific toxic profile or severe systemic outcomes resulting from overdose.
Management Management relies on symptomatic and supportive treatment. No specific antidote is known or required.

When to Seek Urgent Medical Attention

The mandate to seek urgent medical help is driven by the potential for severe adverse events, not a documented toxic effect of the organism itself. Immediate medical attention is required if any signs of a severe systemic reaction occur, such as difficulty breathing, hives, or swelling of the face, tongue, or throat. These are signs of a severe allergic reaction (anaphylaxis) which, while rare for this product, necessitates emergency services contact. General medical advice should be sought if common adverse effects like gas or bloating become severe or if symptoms of an underlying condition worsen.

Therapeutic Uses of Lactospore

Lactospore (Bacillus coagulans MTCC 5856) is used across specific therapeutic domains to provide supportive relief and maintain comfort during periods of digestive instability. The primary benefit is helping to ease the overall burden of chronic and acute gastrointestinal symptoms often linked to an unbalanced intestinal microecology.

It is commonly used to help manage core symptomatic clusters, particularly in conditions characterized by periods of heightened symptoms, such as Irritable Bowel Syndrome (IBS). The preparation is used for addressing symptoms in conditions such as Irritable Bowel Syndrome (IBS), acute episodes of diarrhea, and situations involving functional gas and bloating.

The preparation is relevant when supportive symptom management is appropriate in conditions associated with acute episodes of diarrhea in adults and children, or in contexts involving temporary physiological imbalance, such as during antibiotic therapy.

“This supportive action may assist with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.”

Quick Fact: Relief for Functional Discomfort

Lactospore may be part of symptomatic management when the goal is to ease recurring abdominal pain and supports the management of irregular bowel function, helping patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lactospore?

This eligibility profile for Lactospore (Bacillus coagulans MTCC 5856) is defined by its regulatory status as a Generally Recognized As Safe (GRAS) food ingredient in the United States, rather than as a traditionally approved pharmaceutical drug.

Eligibility Profile Based on Regulatory Filings

The U.S. Food and Drug Administration (FDA) has recognized the ingredient as GRAS for use as a probiotic in numerous specified food categories, permitting its use for the general population.

Officially Documented Exclusions:

Population Group Eligibility Status (as documented) Regulatory Basis
Infants and Toddlers Not Proposed for use in foods intended for these populations (e.g., infant formulas). U.S. FDA GRAS Notice
Users of Meat/Poultry Products Not Intended for use in products under USDA jurisdiction. U.S. FDA GRAS Notice

Contraindications and Restrictions

Formal contraindications (conditions where the substance must not be used) are not listed in the official government regulatory sources examined. Eligibility constraints primarily relate to age group and product type, reflecting limitations set by the ingredient's intended use under the GRAS assessment. There are no explicitly documented, condition-specific (e.g., renal or hepatic impairment) or formal pregnancy/lactation eligibility limitations in the relevant U.S. FDA documentation.

What should I know about interactions with other medicines?

The interaction profile for Lactospore (Bacillus coagulans MTCC 5856) is defined by its status as a live microbial ingredient and does not include documentation for traditional drug-drug pharmacokinetic interactions, such as those involving CYP enzymes or drug transport proteins. The documented interaction patterns focus exclusively on microbial viability and host compatibility as described in regulatory-aligned safety and administration guidance.

Documented Pharmacodynamic Interactions

Interaction Scope Official Regulatory Information
Pharmacodynamic Interaction Oral Anti-Infective Agents (Antibiotics, Antifungals) may reduce the viability and intended effect of the live microbial agent.
Timing Requirement A mandatory temporal separation of at least two hours between the administration of the probiotic and the anti-infective medicine is required to mitigate the loss of viability.

Population-Specific Caution

Population-Specific Interaction Official Regulatory Information
Immunocompromised Individuals Use of any live microbial product in individuals with compromised immune systems (e.g., those receiving immunosuppressive therapy or with severe illness) carries an officially acknowledged increased risk of systemic infection or colonization.

The product's interaction structure is based on a required administration timing rule with anti-infective medicines, necessary to preserve microbial integrity. A major host compatibility caution is noted for immunocompromised populations due to the presence of the live bacterial strain. No combination is formally classified as contraindicated due to a pharmacokinetic interaction.

Mechanism of Action

The mechanism of Bacillus coagulans MTCC 5856 (LactoSpore^ extregistered) is a biological process entirely confined to peripheral activity within the gastrointestinal tract. The primary mechanistic step involves the unique, resilient bacterial spore structure, which confers resistance to the acidic environment of the stomach. Upon reaching the small intestine, the spore undergoes germination into a metabolically active vegetative cell.

These active cells immediately engage in competitive exclusion against potentially disruptive microorganisms by competing for nutrients. They also synthesize and release L(+) Lactic Acid, which contributes to the reduction of the luminal pH—an environmental change inhibitory to many pathogens and metabolically suitable for certain acid-tolerant microbial species.

The mechanistic activity further modulates the host's tissue by producing Short-Chain Fatty Acids (SCFAs) that serve as a primary energy source for the colonocytes (intestinal lining cells). This trophic support contributes to the maintenance of the structural integrity of the epithelial barrier by stabilizing tight junction proteins and reducing paracellular permeability. This mechanism also engages pathways associated with local inflammatory signaling within the gut mucosa, resulting in a modulation of the cytokine profile toward a less pro-inflammatory state.

Dosage and Administration Information

Lactospore is a commercial preparation containing the spore-forming microorganism Bacillus coagulans MTCC 5856 (formerly Lactobacillus sporogenes) and is generally recognized as safe (GRAS) for use as a food ingredient.

Administration and Dosage

Bacillus coagulans is available in various dosage forms, including capsules, tablets, and powders, which can be mixed into food or beverages. Its spore-forming nature allows the bacterium to be highly resistant to heat and stomach acid, ensuring the microorganisms can survive and reach the intestines where they become active.

Clinical studies have explored various dosages, with common amounts ranging from 1 to 2 billion colony-forming units (CFU) daily. For example, in studies involving the management of certain gastrointestinal symptoms in adults, a daily dose of 2 imes 10^9 CFU (2 billion spores) has been used safely for periods up to 90 days.

Key Considerations for Use:

Consideration Instruction
Timing with Antibiotics If taking an antibiotic, separate the use of the probiotic by at least 2 hours to help maintain the probiotic's effectiveness.
Special Populations The use of B. coagulans in pregnant or breastfeeding individuals, as well as in children (especially premature infants), should only be undertaken after consulting a healthcare professional due to limited safety data in these groups.

It is essential to follow the specific instructions and recommended dosage provided on the product label or as directed by a healthcare provider. If you are taking immunosuppressant medications or have a compromised immune system, consult your doctor before using any probiotic supplement.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lactospore

The information below research describes the clinical research that was studied for the specific bacterial strain Bacillus coagulans MTCC 5856 (Lactospore). This overview focuses on the types of studies conducted and what they research examined, and what evidence is limited or still emerging, without providing any medical guidance.

## Evidence for Use in Irritable Bowel Syndrome (IBS) and Acute Diarrhea

Research has explored the strain's role in conditions characterized by fluctuating or episodic manifestations that reflect systemic or functional imbalance. This includes Randomized Controlled Trials (RCTs) that was studied for adults with the diarrhea-predominant subtype of IBS. Researchers studies explored outcomes related to physical discomfort (like abdominal pain and bloating scores) and how stool consistency changed over time.

In these studies, studies report how symptoms evolved in the observed populations over follow-up durations often limited to three months or less. The existing evidence comes mostly from pilot-scale trials where sample sizes were modest.

Separately, research was evaluated in settings that included non-hospitalized children experiencing acute episodes of diarrhea. The outcomes describing episodic or acute changes that research examined included the duration of the diarrhea and the number of bowel movements per day. Evidence is limited for this specific strain in this context, and findings were mixed or varied in some studies.

## Evidence in Special Populations and Research Uncertainty

Evidence is limited for long-term effects are not fully established for Bacillus coagulans MTCC 5856 due to follow-up durations were limited across most research. This means that research data show patterns related to short-term changes, but long-term effects are not fully established.

The evidence landscape includes research applied in studies examining patient-reported experiences in specific groups, such as children and adults with co-occurring major depressive symptoms in the context of IBS. Exploratory pilot research studies monitored these small groups over 90-day periods, tracking standardized mood scoring scales alongside intestinal symptoms.

The certainty remains low in several areas because sample sizes were modest in key trials. Evidence highlights what is known — and what is still uncertain, noting that more research is ongoing and required to fully characterize the observed patterns.

Frequently Asked Questions (FAQ)

Common questions about Lactospore (FAQ)

Q: Is there an environmental concern for disposal of Lactospore?

Official disposal protocols state that unused product or waste should not be discarded into sewers or waterways. Disposal is required to be managed through a licensed waste disposal contractor.

Q: Is it possible to take too much Lactospore, and what would happen?

Official safety reviews classify the ingredient as Generally Recognized As Safe (GRAS) for its intended uses. Adverse events reported during clinical studies are observed at rates similar to those in the placebo (sugar pill) groups, and no serious adverse events have been reported in human trials. Theoretical risks may be noted for specific high-risk groups.

Q: Does Lactospore have an effect on mental health or the gut-brain axis?

Studies have explored the potential link between gut health and mood. Exploratory pilot research has included monitoring standardized mood scoring scales in adults experiencing co-occurring major depressive symptoms alongside Irritable Bowel Syndrome (IBS). These are early findings, and this area of research is ongoing.

Q: Why are there different strengths or colony-forming unit (CFU) counts for Lactospore products?

Product information indicates that clinical studies have explored various dosages for Bacillus coagulans MTCC 5856. Common amounts used in these studies have ranged from 1 to 2 billion colony-forming units (CFU) daily. This variation reflects the different amounts studied for potential benefit.

Q: Are there different forms of Lactospore available, like gummies or liquids?

According to the official product information, the active ingredient, Bacillus coagulans, is available in several dosage forms. These commonly include capsules, tablets, and powders which can be mixed into food or beverages.

Q: Is it normal to feel no difference at all when taking Lactospore?

Official safety data indicates that adverse events reported in clinical studies are generally observed at rates similar to those in the placebo groups. This means that a person may not feel any noticeable effects, positive or adverse, when taking the product.

Q: Does Lactospore interact with common prescription medications like blood pressure pills?

The documented interaction profile for Lactospore is based on maintaining the viability of the microbial agent and host compatibility. Official regulatory documents state that no documentation exists for traditional drug-drug pharmacokinetic interactions, such as those involving CYP enzymes or drug transport proteins.

Q: Does Lactospore require activation, or is it active immediately upon ingestion?

Lactospore is a resilient bacterial spore that is designed to survive the acidic environment of the stomach. The spore is inactive upon ingestion and only undergoes germination—the process of activation—into a metabolically active cell upon reaching the small intestine.

How should Lactospore be stored and disposed of?

How to Store and Dispose of Lactospore

The official requirements for storing Lactospore (Bacillus coagulans MTCC 5856) are designed to maintain the stability of the bacterial spores under general conditions.

Official Storage Conditions

Requirement Specifics
Temperature Store at Controlled Room Temperature (20 C to 25 C), which permits temporary excursions up to 30 C.
Protection Keep in a cool, dry place and protected from direct sunlight.

The product must remain in its original container and be kept tightly closed and sealed to ensure integrity. It is mandatory to keep this and all medicines out of the sight and reach of children.

Disposal

Official disposal protocols require caution to prevent environmental contamination. Unused product or waste should not be discarded into sewers or waterways. For large quantities, disposal must be managed through a licensed waste disposal contractor.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lactospore found in:

A-Z Index: